Clinical Trials · NCT04736199
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Bayer
- Enrollment
- 669
- Start date
- Feb 2021
- Locations
- 131 sites, 15 countries
- Primary endpoint
- Radiological Progression-free Survival (rPFS) Assessed by Central Review